Cell-Based Flu Vaccine Hits Commercial Scale
"The use of cell-based technology for the production of influenza vaccines represents one of the most significant advances in the history of influenza vaccine production. Seqirus is currently the second-largest flu vaccine provider in the world, trumped only by Sanofi Pasteur. Of those four companies, notes the report, "only one has an egg-based vaccine manufacturing facility in the United States." Using a non-egg-based model, Seqirus says, will increase the speed and output of vaccine production. In total, Seqirus operates three major influenza vaccine manufacturing sites: The Holly Springs site (which harnesses cell-culture technology); one in Liverpool, United Kingdom; and another in Melbourne, Australia.Flu Vaccine Not as EffectiveFLU VACCINE ABOUT 42-PERCENT EFFECTIVE. Share This Story:TwitterFacebookLinkedinMoreThe flu vaccine was less effect in the recent flu season. Flu shots are recommended for everyone over age 6 months. But, CDC officials say the vaccine little protection for those over age 65. They're much more likely to land in the hospital or die from the virus than other age groups.
collected by :Lucy William
No comments:
Post a Comment